Israel - English - Ministry of Health

astrazeneca (israel) ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 20 mg - rosuvastatin - rosuvastatin - treatment of adults with:• primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate.• homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate

Israel - English - Ministry of Health

astrazeneca (israel) ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 40 mg - rosuvastatin - rosuvastatin - treatment of adults with:• primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate.• homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 1 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 2 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 4 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 6 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 8 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; hypromellose; magnesium stearate; croscarmellose sodium; sucrose; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate sandoz is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes. fenofibrate sandoz is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. fenofibrate sandoz does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fenofibrate, quantity: 145 mg - tablet - excipient ingredients: sodium lauryl sulfate; silicon dioxide; sucrose; pregelatinised maize starch; microcrystalline cellulose; sodium stearylfumarate; hypromellose; crospovidone; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes.